Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1994;3(5):315–321. doi: 10.1155/S0962935194000438

A reasonable Approach for the Treatment of HIV Infection in the Early Phase with Ozonetherapy (Autohaemotherapy). How ‘Inflammatory’ Cytokines may have A therapeutic Role

V Bocci 1
PMCID: PMC2365573  PMID: 18475574

Abstract

Immunoregulatory cytokines produced by the TH1 subset and by CD8+ T lymphocytes appear to brake naturally and sometimes arrest the progress of HIV infection in the early phase. It appears reasonable to assume that a mild and equilibrated stimulation of the immune system may prevent or delay the fatal transition towards the prevalent production of TH2-type cytokines. The problem is how to stimulate the immune system in a physiological fashion. In the last 7 years we have clarified the main mechanisms of action of an unorthodox immunotherapeutic method first used 40 years ago. Optimized autohaemotherapy after a brief exposure ofblood to ozone may today afford the trick of reprogramming the immune system to keep HIV at bay. The autohaemotherapeutic procedure is simple, safe, inexpensive and most likely is more effective than conventional approaches.

Full Text

The Full Text of this article is available as a PDF (807.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akey D. H., Walton T. E. Liquid-phase study of ozone inactivation of Venezuelan equine encephalomyelitis virus. Appl Environ Microbiol. 1985 Oct;50(4):882–886. doi: 10.1128/aem.50.4.882-886.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bednarik D. P., Mosca J. D., Raj N. B., Pitha P. M. Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon. Proc Natl Acad Sci U S A. 1989 Jul;86(13):4958–4962. doi: 10.1073/pnas.86.13.4958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bocci V., Luzzi E., Corradeschi F., Paulesu L., Di Stefano A. Studies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res. 1993 Apr;12(2):121–126. [PubMed] [Google Scholar]
  4. Bocci V., Luzzi E., Corradeschi F., Paulesu L., Rossi R., Cardaioli E., Di Simplicio P. Studies on the biological effects of ozone: 4. Cytokine production and glutathione levels in human erythrocytes. J Biol Regul Homeost Agents. 1993 Oct-Dec;7(4):133–138. [PubMed] [Google Scholar]
  5. Bocci V. May hyperbaric oxygenation be useful to patients with AIDS? J Biol Regul Homeost Agents. 1987 Oct-Dec;1(4):201–201. [PubMed] [Google Scholar]
  6. Bocci V. Ozonization of blood for the therapy of viral diseases and immunodeficiencies. A hypothesis. Med Hypotheses. 1992 Sep;39(1):30–34. doi: 10.1016/0306-9877(92)90136-z. [DOI] [PubMed] [Google Scholar]
  7. Bocci V., Paulesu L. Studies on the biological effects of ozone 1. Induction of interferon gamma on human leucocytes. Haematologica. 1990 Nov-Dec;75(6):510–515. [PubMed] [Google Scholar]
  8. Bocci V. Roles of interferon produced in physiological conditions. A speculative review. Immunology. 1988 May;64(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  9. Bourinbaiar A. S., Nagorny R. Inhibitory effect of natural interferon alpha on human immunodeficiency virus type 1 transmission from epithelial cells to lymphocytes in vitro. Eur J Pharmacol. 1993 Jan 5;230(1):15–22. doi: 10.1016/0014-2999(93)90404-6. [DOI] [PubMed] [Google Scholar]
  10. Brinchmann J. E., Gaudernack G., Vartdal F. CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. J Immunol. 1990 Apr 15;144(8):2961–2966. [PubMed] [Google Scholar]
  11. Buckley R. D., Hackney J. D., Clark K., Posin C. Ozone and human blood. Arch Environ Health. 1975 Jan;30(1):40–43. doi: 10.1080/00039896.1975.10666631. [DOI] [PubMed] [Google Scholar]
  12. Carpendale M. T., Freeberg J. K. Ozone inactivates HIV at noncytotoxic concentrations. Antiviral Res. 1991 Oct;16(3):281–292. doi: 10.1016/0166-3542(91)90007-e. [DOI] [PubMed] [Google Scholar]
  13. Carpendale M. T., Freeberg J., Griffiss J. M. Does ozone alleviate AIDS diarrhea? J Clin Gastroenterol. 1993 Sep;17(2):142–145. doi: 10.1097/00004836-199309000-00010. [DOI] [PubMed] [Google Scholar]
  14. Cassatella M. A., Meda L., Bonora S., Ceska M., Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med. 1993 Dec 1;178(6):2207–2211. doi: 10.1084/jem.178.6.2207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Clerici M., Lucey D. R., Berzofsky J. A., Pinto L. A., Wynn T. A., Blatt S. P., Dolan M. J., Hendrix C. W., Wolf S. F., Shearer G. M. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science. 1993 Dec 10;262(5140):1721–1724. doi: 10.1126/science.7903123. [DOI] [PubMed] [Google Scholar]
  16. Clerici M., Shearer G. M. A TH1-->TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993 Mar;14(3):107–111. doi: 10.1016/0167-5699(93)90208-3. [DOI] [PubMed] [Google Scholar]
  17. D'Andrea A., Aste-Amezaga M., Valiante N. M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med. 1993 Sep 1;178(3):1041–1048. doi: 10.1084/jem.178.3.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. DeStefano E., Friedman R. M., Friedman-Kien A. E., Goedert J. J., Henriksen D., Preble O. T., Sonnabend J. A., Vilcek J. Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis. 1982 Oct;146(4):451–459. doi: 10.1093/infdis/146.4.451. [DOI] [PubMed] [Google Scholar]
  19. Del Prete G., De Carli M., Almerigogna F., Giudizi M. G., Biagiotti R., Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 1993 Jan 15;150(2):353–360. [PubMed] [Google Scholar]
  20. Fauci A. S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988 Feb 5;239(4840):617–622. doi: 10.1126/science.3277274. [DOI] [PubMed] [Google Scholar]
  21. Finkelman F. D., Katona I. M., Urban J. F., Jr, Holmes J., Ohara J., Tung A. S., Sample J. V., Paul W. E. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol. 1988 Oct 1;141(7):2335–2341. [PubMed] [Google Scholar]
  22. Freeman B. A., Mudd J. B. Reaction of ozone with sulfhydryls of human erythrocytes. Arch Biochem Biophys. 1981 Apr 15;208(1):212–220. doi: 10.1016/0003-9861(81)90142-9. [DOI] [PubMed] [Google Scholar]
  23. Garber G. E., Cameron D. W., Hawley-Foss N., Greenway D., Shannon M. E. The use of ozone-treated blood in the therapy of HIV infection and immune disease: a pilot study of safety and efficacy. AIDS. 1991 Aug;5(8):981–984. doi: 10.1097/00002030-199108000-00009. [DOI] [PubMed] [Google Scholar]
  24. Goldstein B. D., Balchum O. J. Effect of ozone on lipid peroxidation in the red blood cell. Proc Soc Exp Biol Med. 1967 Nov;126(2):356–358. doi: 10.3181/00379727-126-32444. [DOI] [PubMed] [Google Scholar]
  25. Groopman J. E., Feder D. Hematopoietic growth factors in AIDS. Semin Oncol. 1992 Aug;19(4):408–414. [PubMed] [Google Scholar]
  26. Groopman J. E., Gottlieb M. S., Goodman J., Mitsuyasu R. T., Conant M. A., Prince H., Fahey J. L., Derezin M., Weinstein W. M., Casavante C. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1984 May;100(5):671–676. doi: 10.7326/0003-4819-100-5-671. [DOI] [PubMed] [Google Scholar]
  27. Halliwell B., Gutteridge J. M. The antioxidants of human extracellular fluids. Arch Biochem Biophys. 1990 Jul;280(1):1–8. doi: 10.1016/0003-9861(90)90510-6. [DOI] [PubMed] [Google Scholar]
  28. Johnston M. I., Hoth D. F. Present status and future prospects for HIV therapies. Science. 1993 May 28;260(5112):1286–1293. doi: 10.1126/science.7684163. [DOI] [PubMed] [Google Scholar]
  29. June C. H., Bluestone J. A., Nadler L. M., Thompson C. B. The B7 and CD28 receptor families. Immunol Today. 1994 Jul;15(7):321–331. doi: 10.1016/0167-5699(94)90080-9. [DOI] [PubMed] [Google Scholar]
  30. Kekow J., Wachsman W., McCutchan J. A., Gross W. L., Zachariah M., Carson D. A., Lotz M. Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J Clin Invest. 1991 Mar;87(3):1010–1016. doi: 10.1172/JCI115059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kiniwa M., Gately M., Gubler U., Chizzonite R., Fargeas C., Delespesse G. Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest. 1992 Jul;90(1):262–266. doi: 10.1172/JCI115846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lane H. C. The role of alpha-interferon in patients with human immunodeficiency virus infection. Semin Oncol. 1991 Oct;18(5 Suppl 7):46–52. [PubMed] [Google Scholar]
  33. Levine A. S., Sivulich M., Wiernik P. H., Levy H. B. Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer. Cancer Res. 1979 May;39(5):1645–1650. [PubMed] [Google Scholar]
  34. Levy J. A. HIV pathogenesis and long-term survival. AIDS. 1993 Nov;7(11):1401–1410. doi: 10.1097/00002030-199311000-00001. [DOI] [PubMed] [Google Scholar]
  35. Lewis D. B., Wilson C. B. Gamma-interferon: an immunoregulatory lymphokine with immunotherapeutic potential. Pediatr Infect Dis J. 1990 Sep;9(9):642–651. [PubMed] [Google Scholar]
  36. Lotze M. T., Matory Y. L., Rayner A. A., Ettinghausen S. E., Vetto J. T., Seipp C. A., Rosenberg S. A. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986 Dec 15;58(12):2764–2772. doi: 10.1002/1097-0142(19861215)58:12<2764::aid-cncr2820581235>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  37. Lähdevirta J., Maury C. P., Teppo A. M., Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Sep;85(3):289–291. doi: 10.1016/0002-9343(88)90576-1. [DOI] [PubMed] [Google Scholar]
  38. Mackensen A., Galanos C., Engelhardt R. Treatment of cancer patients with endotoxin induces release of endogenous cytokines. Pathobiology. 1991;59(4):264–267. doi: 10.1159/000163659. [DOI] [PubMed] [Google Scholar]
  39. Mellors J. W., Griffith B. P., Ortiz M. A., Landry M. L., Ryan J. L. Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis. 1991 Jan;163(1):78–82. doi: 10.1093/infdis/163.1.78. [DOI] [PubMed] [Google Scholar]
  40. Michaelis B., Levy J. A. HIV replication can be blocked by recombinant human interferon beta. AIDS. 1989 Jan;3(1):27–31. [PubMed] [Google Scholar]
  41. Molina J. M., Scadden D. T., Byrn R., Dinarello C. A., Groopman J. E. Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest. 1989 Sep;84(3):733–737. doi: 10.1172/JCI114230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Murphy P. M., Lane H. C., Gallin J. I., Fauci A. S. Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma. Ann Intern Med. 1988 Jan;108(1):36–41. doi: 10.7326/0003-4819-108-1-36. [DOI] [PubMed] [Google Scholar]
  43. Murray H. W., Rubin B. Y., Masur H., Roberts R. B. Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med. 1984 Apr 5;310(14):883–889. doi: 10.1056/NEJM198404053101404. [DOI] [PubMed] [Google Scholar]
  44. Pantaleo G., Graziosi C., Fauci A. S. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993 Feb 4;328(5):327–335. doi: 10.1056/NEJM199302043280508. [DOI] [PubMed] [Google Scholar]
  45. Paulesu L., Luzzi E., Bocci V. Studies on the biological effects of ozone: 2. Induction of tumor necrosis factor (TNF-alpha) on human leucocytes. Lymphokine Cytokine Res. 1991 Oct;10(5):409–412. [PubMed] [Google Scholar]
  46. Perno C. F., Yarchoan R., Cooney D. A., Hartman N. R., Webb D. S., Hao Z., Mitsuya H., Johns D. G., Broder S. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med. 1989 Mar 1;169(3):933–951. doi: 10.1084/jem.169.3.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Poli G., Kinter A., Justement J. S., Kehrl J. H., Bressler P., Stanley S., Fauci A. S. Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A. 1990 Jan;87(2):782–785. doi: 10.1073/pnas.87.2.782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Pryor W. A. Ozone in all its reactive splendor. J Lab Clin Med. 1993 Nov;122(5):483–486. [PubMed] [Google Scholar]
  49. Rios A., Mansell P. W., Newell G. R., Reuben J. M., Hersh E. M., Gutterman J. U. Treatment of acquired immunodeficiency syndrome--related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol. 1985 Apr;3(4):506–512. doi: 10.1200/JCO.1985.3.4.506. [DOI] [PubMed] [Google Scholar]
  50. Siegel J. P., Lane H. C., Stocks N. I., Quinnan G. V., Jr, Fauci A. S. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome. J Biol Response Mod. 1985 Dec;4(6):596–601. [PubMed] [Google Scholar]
  51. Tosato G., Seamon K. B., Goldman N. D., Sehgal P. B., May L. T., Washington G. C., Jones K. D., Pike S. E. Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science. 1988 Jan 29;239(4839):502–504. doi: 10.1126/science.2829354. [DOI] [PubMed] [Google Scholar]
  52. Walker C. M., Levy J. A. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology. 1989 Apr;66(4):628–630. [PMC free article] [PubMed] [Google Scholar]
  53. Weiss R. A. How does HIV cause AIDS? Science. 1993 May 28;260(5112):1273–1279. doi: 10.1126/science.8493571. [DOI] [PubMed] [Google Scholar]
  54. Wells K. H., Latino J., Gavalchin J., Poiesz B. J. Inactivation of human immunodeficiency virus type 1 by ozone in vitro. Blood. 1991 Oct 1;78(7):1882–1890. [PubMed] [Google Scholar]
  55. Westermann J., Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig. 1992 Jul;70(7):539–544. doi: 10.1007/BF00184787. [DOI] [PubMed] [Google Scholar]
  56. Wood R., Montoya J. G., Kundu S. K., Schwartz D. H., Merigan T. C. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis. 1993 Mar;167(3):519–525. doi: 10.1093/infdis/167.3.519. [DOI] [PubMed] [Google Scholar]
  57. Yamada O., Hattori N., Kurimura T., Kita M., Kishida T. Inhibition of growth of HIV by human natural interferon in vitro. AIDS Res Hum Retroviruses. 1988 Aug;4(4):287–294. doi: 10.1089/aid.1988.4.287. [DOI] [PubMed] [Google Scholar]
  58. Yarchoan R., Mitsuya H., Broder S. Challenges in the therapy of HIV infection. Immunol Today. 1993 Jun;14(6):303–309. doi: 10.1016/0167-5699(93)90050-U. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES